JOURNAL ARTICLE

RHCG and TCAF1 promoter hypermethylation predicts biochemical recurrence in prostate cancer patients treated by radical prostatectomy

Abstract

Methylation of the RHCG-TCAF1 panel adds significant independent prognostic value to established prognostic parameters for prostate cancer and thus may help to guide treatment decisions in the future. Further investigation in large independent cohorts is necessary before translation into clinical utility.

Keywords:
Prostatectomy Medicine Prostate cancer Biochemical recurrence DNA methylation Urology Prostate Cancer Oncology Internal medicine Cancer research Gene expression Gene Biology

Metrics

30
Cited By
4.03
FWCI (Field Weighted Citation Impact)
42
Refs
0.94
Citation Normalized Percentile
Is in top 1%
Is in top 10%

Citation History

Topics

Prostate Cancer Treatment and Research
Health Sciences →  Medicine →  Pulmonary and Respiratory Medicine
Epigenetics and DNA Methylation
Life Sciences →  Biochemistry, Genetics and Molecular Biology →  Molecular Biology
Prostate Cancer Diagnosis and Treatment
Health Sciences →  Medicine →  Pulmonary and Respiratory Medicine

Related Documents

© 2026 ScienceGate Book Chapters — All rights reserved.